Lindsay Bealor Greenleaf talks to Policy & Medicine about Azar’s plan to move drugs from Part B to D
Health policy expert and director at ADVI Health, Lindsay Bealor Greenleaf, commented on Secretary Azar’s testimony, stating, “It was great to hear Secretary Azar emphasize the need to reform the role played by PBMs, but his plan for moving Medicare Part B drug coverage into Part D is concerning. Drugs reimbursed under Part B are those that are administered by physician, as opposed to drugs reimbursed under Part D where a patient purchases the drug at the pharmacy counter. Physician-administered products have highly complex storage, handling and administration issues that justify treating these products differently from drugs that are obtained through the retail pharmacy setting.”
[el-text]
Written by Thomas Sullivan
***excerpt***
Health policy expert and director at ADVI Health, Lindsay Bealor Greenleaf, commented on Secretary Azar’s testimony, stating, “It was great to hear Secretary Azar emphasize the need to reform the role played by PBMs, but his plan for moving Medicare Part B drug coverage into Part D is concerning. Drugs reimbursed under Part B are those that are administered by physician, as opposed to drugs reimbursed under Part D where a patient purchases the drug at the pharmacy counter. Physician-administered products have highly complex storage, handling and administration issues that justify treating these products differently from drugs that are obtained through the retail pharmacy setting.”
***end excerpt***
***
[/el-text]
View full article here
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.